Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT03618381 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT03618381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03618381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 18, 2019
Completion date
June 30, 2040
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, clear cell sarcoma, desmoplastic small round cell tumor, ewing sarcoma, germ cell tumor, hepatoblastoma, malignant peripheral nerve sheath tumors, neuroblastoma, osteosarcoma, pediatric solid tumor, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, soft tissue sarcoma, synovial sarcoma, wilms tumor